Truist Securities Maintains Buy on Nurix Therapeutics, Raises Price Target to $32

Benzinga Newsdesk www.benzinga.com Positive 82.5%

Neg 0% Neu 0% Pos 82.5%

Truist Securities analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $30 to $32.